 <h1>Takhzyro Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>lanadelumab</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about lanadelumab. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Takhzyro.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to lanadelumab: subcutaneous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, lanadelumab (the active ingredient contained in Takhzyro) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking lanadelumab:</p><p>
<i>More common</i>
</p><ul>
<li>Rash</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Fast heartbeat</li>
<li>fever</li>
<li>hives, itching</li>
<li>hoarseness</li>
<li>irritation</li>
<li>joint pain, stiffness, or swelling</li>
<li>redness of the skin</li>
<li>swelling of the eyelids, face, lips, hands, or feet</li>
<li>tightness in the chest</li>
<li>troubled breathing or swallowing</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of lanadelumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
<li>body aches or pain</li>
<li>chills</li>
<li>cough</li>
<li>difficulty in moving</li>
<li>dizziness</li>
<li>ear congestion</li>
<li>headache</li>
<li>loss of voice</li>
<li>muscle ache, cramps, pain, or stiffness</li>
<li>nasal congestion</li>
<li>runny nose</li>
<li>sneezing</li>
<li>sore throat</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Diarrhea</li>
</ul><p>
<!-- end subcutaneous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to lanadelumab: subcutaneous solution</i></p><h3>General</h3><p>The most common adverse reactions were injection site reactions, upper respiratory infection, headache, rash, myalgia, dizziness, and diarrhea.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory infection (up to 44%)</p>
<p><b>Frequency not reported</b>: Viral upper respiratory infection<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 33%), dizziness (up to 10%)</p>
<p><b>Frequency not reported</b>: Tension headache, sinus headache<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Anti-drug antibody (ADA)-positive sample during treatment with this drug (12%)</p>
<p><b>Common</b> (1% to 10%): Hypersensitivity<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Myalgia (up to 11%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 11%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): ALT increased, AST increased, ALT or AST greater than 8 times the upper limit of normal<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection site reactions (up to 56%)</p>
<p><b>Frequency not reported</b>: Pain, erythema, bruising, hematoma, hemorrhage, pruritus, swelling, induration, paresthesia, warmth, edema, rash<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (up to 10%)</p>
<p><b>Frequency not reported</b>: Maculopapular rash, erythematous rash<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Takhzyro (lanadelumab)." Dyax Corporation, Cambridge, MA. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What type of drug is Takhzyro?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Takhzyro (lanadelumab)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: miscellaneous coagulation modifiers</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Takhzyro &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Hereditary Angioedema</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to lanadelumab: subcutaneous solution</i></p><h3>General</h3><p>The most common adverse reactions were injection site reactions, upper respiratory infection, headache, rash, myalgia, dizziness, and diarrhea.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory infection (up to 44%)</p><p><b>Frequency not reported</b>: Viral upper respiratory infection<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 33%), dizziness (up to 10%)</p><p><b>Frequency not reported</b>: Tension headache, sinus headache<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Anti-drug antibody (ADA)-positive sample during treatment with this drug (12%)</p><p><b>Common</b> (1% to 10%): Hypersensitivity<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Myalgia (up to 11%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 11%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): ALT increased, AST increased, ALT or AST greater than 8 times the upper limit of normal<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection site reactions (up to 56%)</p><p><b>Frequency not reported</b>: Pain, erythema, bruising, hematoma, hemorrhage, pruritus, swelling, induration, paresthesia, warmth, edema, rash<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (up to 10%)</p><p><b>Frequency not reported</b>: Maculopapular rash, erythematous rash<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Takhzyro (lanadelumab)." Dyax Corporation, Cambridge, MA. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What type of drug is Takhzyro?</li>
</ul><h2>More about Takhzyro (lanadelumab)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: miscellaneous coagulation modifiers</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Takhzyro &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Hereditary Angioedema</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>